Yale's Colton Center for Autoimmunity has selected nine researchers for nearly $1 million in 2025 funding, backing projects that apply AI, nanoparticles, and novel biologics to autoimmune disease.
Yale researchers have found that a lupus-related antibody can penetrate "cold" tumors and activate immune responses — offering a promising new approach to treating glioblastoma and other hard-to-treat cancers.
NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
Yale's Colton Center for Autoimmunity has awarded 2022 grants to six projects spanning lupus, multiple sclerosis, pediatric OCD, and systemic sclerosis — all targeting new diagnostics, therapies, or disease mechanisms.
Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.
Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.
